Literature DB >> 12398951

Morphological, histomorphometric, and microstructural alterations in human bone metastasis from breast carcinoma.

S Vukmirovic-Popovic1, N Colterjohn, S Lhoták, W C M Duivenvoorden, F W Orr, G Singh.   

Abstract

Bone is one of the most common sites of breast cancer metastasis. Metastases are often associated with bone destruction and are a major cause of morbidity. We examined structural bone changes induced by metastatic tumor in bone biopsies from 33 patients with metastatic breast carcinoma (20 from patients with pathological femoral fracture and 13 with no fracture) and 20 normal controls. In all metastatic biopsies bone remodeling was shown to be tumor volume-dependent. Bone resorption and bone formation were biphasic with both increasing at earlier stages of metastatic bone disease and decreasing later on. A comparison of patients with fracture and no fracture did not reveal statistically significant differences in the extent of bone destruction or trabecular thinning. Bone histomorphometry showed limited ability to explain the higher bone volume loss in fracture patients (decreases of 42% and 25%, respectively, in fracture and nonfracture patients compared with controls). However, changes in bone quality, including increased disconnectivity and decreased connectivity, as evaluated by node-strut analysis, suggested that there were more structural changes in the fracture compared with the nonfracture group. The nonfracture group included six patients with no radiological evidence of bone metastasis (occult metastasis). They showed a higher tumor volume and a twofold lower eroded surface compared with the rest of the group. The decrease in bone volume (14% lower than controls) was below the limit of X-ray detection. Because we observed no increase in osteoclast-related parameters and no correlation between osteoclast surface and eroded surface, we believe that, in occult metastasis, osteoclastic bone resorption is not an important factor in overall bone resorption. Quantitatively, the eroded surface in direct contact with tumor cells was threefold higher than the osteoclast surface in occult metastasis, whereas the rest of the metastatic group (27 of 33) showed predominantly osteoclast-mediated eroded surface. Node-strut analysis on occult metastasis revealed a significant increase in disconnectivity without a concomitant significant decrease in bone volume and trabecular thinning. We conclude that, in occult metastasis, bone resorption may be more osteoclast-independent and other mechanisms involving the tumor cells may be more prevalent. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12398951     DOI: 10.1016/s8756-3282(02)00847-5

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  9 in total

1.  Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis.

Authors:  Didier Dréau; Amel Karaa; Cathy Culberson; Heather Wyan; Iain H McKillop; Mark G Clemens
Journal:  Clin Exp Metastasis       Date:  2006-07-07       Impact factor: 5.150

2.  Identification of NOG as a specific breast cancer bone metastasis-supporting gene.

Authors:  Maria Tarragona; Milica Pavlovic; Anna Arnal-Estapé; Jelena Urosevic; Mònica Morales; Marc Guiu; Evarist Planet; Eva González-Suárez; Roger R Gomis
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

Review 3.  Bisphosphonate treatment and radiotherapy in metastatic breast cancer.

Authors:  A Ugur Ural; Ferit Avcu; Yusuf Baran
Journal:  Med Oncol       Date:  2008-01-17       Impact factor: 3.064

Review 4.  The effects of metastatic lesion on the structural determinants of bone: Current clinical and experimental approaches.

Authors:  Stacyann Bailey; David Hackney; Deepak Vashishth; Ron N Alkalay
Journal:  Bone       Date:  2019-11-21       Impact factor: 4.398

5.  Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo.

Authors:  H K Brown; P D Ottewell; C A Evans; I Holen
Journal:  Clin Exp Metastasis       Date:  2012-05-06       Impact factor: 5.150

6.  Cancer cell lines release glutamate into the extracellular environment.

Authors:  Eric P Seidlitz; Mohit K Sharma; Zeina Saikali; Michelle Ghert; Gurmit Singh
Journal:  Clin Exp Metastasis       Date:  2009-06-13       Impact factor: 5.150

7.  The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis.

Authors:  Chiara Secondini; Antoinette Wetterwald; Ruth Schwaninger; George N Thalmann; Marco G Cecchini
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

8.  Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain.

Authors:  Jennifer Fazzari; Hanxin Lin; Cecilia Murphy; Robert Ungard; Gurmit Singh
Journal:  Sci Rep       Date:  2015-02-11       Impact factor: 4.379

9.  Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.

Authors:  Laura S Gregory; Wilson Choi; Leslie Burke; Judith A Clements
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.